DB05222InvestigationalProtein Based Therapies
KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.
- Mechanism
- Curator reviewed
KB001 targets and neutralizes the PcrV protein of the Type III secretion system of the Pseudomonas bacterium, which directly inhibits its toxic effects. This mechanism of action is different from that of other antibiotics and represents a new approach in the treatment of bacterial infections.
- Primary indication
- For the treatment of infections caused by multi-drug resistant Pseudomonas aeruginosa.Curator reviewed
- Code names
- KB001
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with KB001, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account